MANNKIND CORP
MNKD · XNASCIK 899460fmd_0PJ4DVTE6RHWM7F0X0B99Z8G0EManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Mar 01, 1992 to Sep 30, 2026, 83 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 175 | 12 | 28 | 63 | 65 | 75 | 100 | 199 | 286 | 349 |
| Cost of revenue | 17 | 17 | 19 | 20 | 15 | 17 | 16 | 21 | 17 | 27 |
| Gross profit | 158 | (5) | 8 | 43 | 50 | 59 | 84 | 178 | 268 | 322 |
| Research and development | 15 | 14 | 9 | 7 | 6 | 12 | 20 | 31 | 46 | 66 |
| Selling, general and administrative | 47 | 75 | 80 | 75 | 59 | 77 | 91 | 94 | 94 | 144 |
| Total operating expenses | – | – | – | – | 25 | 39 | 57 | 63 | 77 | 88 |
| Operating income | 67 | (108) | (77) | (45) | (48) | (47) | (64) | 9 | 73 | 39 |
| Interest expense | 16 | 9 | 5 | 6 | 9 | 15 | 15 | 15 | 12 | 14 |
| Interest and investment income | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 6 | 13 | 8 |
| Other non-operating income (expense) | 58 | (9) | (10) | (7) | (10) | (34) | (23) | (19) | (42) | (37) |
| Income before taxes | 126 | (117) | (87) | (52) | (57) | (81) | (87) | (10) | 31 | 1 |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 2 | 3 | (4) |
| Net income from continuing operations | 126 | (117) | (87) | (52) | (57) | (81) | (87) | (12) | 28 | 6 |
| Net income | 126 | (117) | (87) | (52) | (57) | (81) | (87) | (12) | 28 | 6 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |